Researchers from The University of Manchester and The Christie NHS Foundation Trust — both part of Manchester Cancer Research Centre — say the test could be developed and used in hospitals within the next few years. …
Cancer arises due to genetic changes which cause normal cells to develop into tumors. As we learn more about breast cancer, we are seeing that it is not one single disease — the mutations in the genes that cause different cancers are not alike, and this is why tumors respond differently to treatment and grow at different rates. Currently, there are two key markers that clinicians use to predict response to treatments. Spotting the trends in tumor genetics and creating a system to diagnose tumor types is a primary objective of cancer scientists. …
Colin Collins and Alexander Wyatt, and other researchers from the Vancouver Prostate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients’ treatment outcomes with the RNA sequence of their prostate cancer tumors. They suggest that similarities between the RNA of some of the patients’ tumors could open up new avenues of treatment. Prostate cancer is the fourth most common cancer worldwide, but can be effectively managed. …
The multi-institutional group, led by scientists at Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center, publish their results in the journal’s online edition on Aug. 24. The researchers suggest their laboratory findings in mouse models of the disease could lead to a more targeted and effective molecular therapy that would also reduce the harmful side effects of current treatments, which include chemotherapy, radiation or surgery. “Although current treatments improve survival rates, patients suffer severe side effects and relapse tumors carry mutations that resist treatment,” said lead investigator Q. …
The findings, set out in the Journal of the National Cancer Institute, are based on the experience of more than 2,000 young women in England and Wales treated for the cancer over a period of more than 40 years. Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of going through the menopause early — but there was insufficient information to provide patients with detailed advice. But the new study, led by scientists at The Institute of Cancer Research, London, provides precise estimates of risk for women depending on which treatment types and doses they received and at what age — allowing doctors to give them detailed advice about their risks of future infertility…
Cancer Research UK scientists have discovered that acral melanomas — the rare type of skin cancer that caused reggae musician Bob Marley’s death — are genetically distinct from other more common types of skin cancer, according to a study published in the journal Pigment Cell & Melanoma Research. Acral melanoma most often affects the palms of the hands, soles of the feet, nail-beds and other hairless parts of the skin. Unlike other more common types of melanoma, it’s not caused by UV damage from the sun. The team, from the Cancer Research UK Manchester Institute at The University of Manchester, sequenced the tumours of five patients with acral melanoma and combined this with data from three other patients. …
“Associations between various respiratory diseases and lung cancer have been shown in earlier studies, but few of these studies considered multiple respiratory diseases simultaneously,” said researcher Ann Olsson, PhD, of the International Agency for Research in Cancer in Lyon, France. …
Analyzing these modifications can provide important clues to the type of tumor a patient has, and how it will respond to different drugs. For example, patients with glioblastoma, a type of brain tumor, respond well to a certain class of drugs known as alkylating agents if the DNA-repair gene MGMT is silenced by epigenetic modification…
Despite there currently being a wide variety of compounds against cancer, they all have serious side effects. Furthermore, tumours are capable of becoming resistant, limiting this type of treatment. …
“This fascinating new finding could help doctors adapt their treatments to patients with bladder cancer,” said Nell Barrie, Cancer Research UK The team from The University of Manchester, funded by the Medical Research Council, found that patients whose bladder tumor had high levels of a protein, called ‘HIF-1α’, were more likely to benefit from having carbogen — oxygen mixed with carbon dioxide gas — and nicotinamide tablets at the same time as their radiotherapy. The treatment, called ‘CON’, makes radiotherapy more effective. By comparing levels of HIF-1α in tissue samples from 137 patients who had radiotherapy on its own or with CON, the researchers found the protein predicted which patients benefited from having CON. High levels of the protein were linked to better survival from the disease when patients had radiotherapy and CON. …